Marimed (MRMD) Net Margin (2011 - 2026)

Marimed (MRMD) has 16 years of Net Margin data on file, last reported at 9.54% in Q1 2026.

• On a quarterly basis, Net Margin rose 491.0% year-over-year to 9.54% in Q1 2026; TTM through Mar 2026 was 7.81%, a 256.0% increase from a year earlier, with the FY2025 full-year figure at 9.04%, down 116.0% from the prior year.
• Net Margin for Q1 2026 stood at 9.54%, up from 11.14% in the prior quarter.
• Over the last five years, Net Margin for MRMD reached as high as 13.56% in Q1 2022 and fell as low as 26.06% in Q4 2023.
• Historically, Net Margin has averaged 4.57% across 5 years, with a median of 3.41% in 2024.
• Across the five-year window, Net Margin soared 3389 bps in 2022 and plunged 3932 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 13.25% in 2022, then slumped by 297 bps to 26.06% in 2023, then increased by 19 bps to 21.22% in 2024, then jumped by 47 bps to 11.14% in 2025, then climbed by 14 bps to 9.54% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 9.54% in Q1 2026, 11.14% in Q4 2025, and 7.21% in Q3 2025.